CAS 284461-73-0 Sorafenib
Port: Tianjin, China
Sorafenib is a new multi-targeted oral drug for the treatment of tumors. Its primary development goal is to treat gastrointestinal stromal tumors and metastatic kidney cells that are not responsive or unbearable to standard therapies.
Sorafenib can selectively target certain proteins of the receptor, which is considered plays a role in molecular switching in the tumor growth process. Its indications have been in the approval by the FDA United States.